Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giuseppe Procopio

Showing results (11-20 of 289) with videos related to

Pageof 29
Sort By:
Cancer Biology & Therapy|November 21, 2013
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profileRoberto Iacovelli, Elena Verzoni, Filippo De Braud, et al.
Cancer Biology & Therapy|February 22, 2014
Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?Roberto Iacovelli, Elena Verzoni, Filippo Maria De Braud, et al.
Anti-Cancer Drugs|November 30, 2011
Abiraterone acetate in castration-resistant prostate cancerRoberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, et al.
Tumori|October 30, 2016
Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapyAlessia Mennitto, Elena Verzoni, Giuseppina Calareso, et al.
Tumori|May 3, 2011
Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: a case reportRosario Mazzola, Massimiliano Alù, Vita Leonardi, et al.
Expert Review of Anticancer Therapy|August 28, 2014
Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancerRoberto Iacovelli, Matteo Santoni, Filippo de Braud, et al.
Tumori|June 9, 2012
New perspectives in advanced genitourinary malignanciesPamela Biondani, Giuseppe Procopio, Filippo Pietrantonio, et al.
Future Oncology (London, England)|May 31, 2013
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitorRoberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Therapeutic Advances in Urology|December 4, 2012
Experience with sorafenib in the treatment of advanced renal cell carcinomaGiuseppe Procopio, Elena Verzoni, Isabella Testa, et al.
Tumori|June 26, 2015
TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinomaElena Verzoni, Paolo Grassi, Rosanna Montone, et al.
Pageof 29

Showing results (11-20 of 289) with videos related to

Sort By:
Pageof 29
Cancer Biology & Therapy|November 21, 2013
First line treatment of metastatic renal cell carcinoma: two standards with different toxicity profileRoberto Iacovelli, Elena Verzoni, Filippo De Braud, et al.
Cancer Biology & Therapy|February 22, 2014
Study design and clinical evidence in mRCC: can we save axitinib as a first-line therapy?Roberto Iacovelli, Elena Verzoni, Filippo Maria De Braud, et al.
Anti-Cancer Drugs|November 30, 2011
Abiraterone acetate in castration-resistant prostate cancerRoberto Iacovelli, Antonella Palazzo, Giuseppe Procopio, et al.
Tumori|October 30, 2016
Treatment of advanced renal cell carcinoma: recent advances and current role of immunotherapy, surgery, and cryotherapyAlessia Mennitto, Elena Verzoni, Giuseppina Calareso, et al.
Tumori|May 3, 2011
Capecitabine in combination with oxaliplatin as first-line therapy for advanced gastric cancer: a case reportRosario Mazzola, Massimiliano Alù, Vita Leonardi, et al.
Expert Review of Anticancer Therapy|August 28, 2014
Highlights from the ASCO Genitourinary Symposium 2014: focus on renal and prostate cancerRoberto Iacovelli, Matteo Santoni, Filippo de Braud, et al.
Tumori|June 9, 2012
New perspectives in advanced genitourinary malignanciesPamela Biondani, Giuseppe Procopio, Filippo Pietrantonio, et al.
Future Oncology (London, England)|May 31, 2013
Metastatic renal cell carcinoma: how to make the best sequencing decision after withdrawal for intolerance to a tyrosine kinase inhibitorRoberto Sabbatini, Cinizia Ortega, Giuseppe Procopio, et al.
Therapeutic Advances in Urology|December 4, 2012
Experience with sorafenib in the treatment of advanced renal cell carcinomaGiuseppe Procopio, Elena Verzoni, Isabella Testa, et al.
Tumori|June 26, 2015
TOKIO rationale and protocol: a phase II study to evaluate the activity and safety of third-line tyrosine kinase inhibitor after 2 tyrosine kinase inhibitors in patients with metastatic renal cell carcinomaElena Verzoni, Paolo Grassi, Rosanna Montone, et al.
Pageof 29